To date, only Schrag et al [65] have addressed secondary cancer risk–reducing strategies in BRCA1 and BRCA2 carriers who underwent BCT for unilateral breast cancer, using decision-analytic models. The gene discussed is BRCA2; the disease is breast cancer.